3'-Methoxyflavonol is a potent, selective agonist of neuromedin U 2 receptor (NMU2R).

CPN-351 TFA (compound 9a) is a pentapeptide that acts as a selective antagonist for human NMUR1, exhibiting a pA2 value of 7.35. Its antagonistic effect on human NMUR1 is ten times stronger than on NMUR2. CPN-351 TFA is applicable in inflammation research.

CPN-267 (compound 7b) TFA is a selective agonist of neuromedin U receptor 1 (NMUR1) with an EC50 of 0.25 nM. This compound inhibits weight gain in mice and is applicable in obesity research.

CPN-351 (compound 9a) is a pentapeptide that acts as a selective antagonist for human NMUR1, with a pA2 value of 7.35. It exhibits ten times greater antagonistic activity toward human NMUR1 compared to NMUR2. CPN-351 is applicable in inflammation research.

Neuromedin U,a 23-amino acid brain-gut peptide, regulates several important physiological functions through its cognate receptor NMUR2 in the central nervous system, including energy balance, stress response, and nociception.

Neuromedin S (human), a 33-amino acid neuropeptide, serves as an endogenous ligand for the orphan G-protein coupled receptor (GPCR) FM-4/TGR-1, and acts on the neuromedin U (NMU) receptor 2 (NMUR2) to regulate body weight homeostasis [1].

CPN-267 (compound 7b) acts as a selective agonist for the neuromediatin U receptor 1 (NMUR1), exhibiting an EC50 value of 0.25 nM. It effectively inhibits weight gain in mice, making it useful for obesity research.

R-PSOP is a potent and selective nonpeptidic NMUR2 antagonist, exhibiting binding affinity to human and rat NMUR2 with Ki values of 52 nM and 32 nM, respectively. This compound demonstrates moderate central nervous system (CNS) penetration and is valuable in the study of eating disorders, obesity, pain, and stress-related disorders [1].

NY0116 is an agonist of the neuromedin U receptor 2 (NMUR2), exhibiting EC50 values of 27.76 μM for hNMUR1 and 13.61 μM for hNMUR2. In NMUR2 stably expressing HEK293 cells, NY0116 reduces cAMP levels while enhancing calcium signaling [1].

CPN-219 is a next-generation hexapeptidic NMUR2 agonist that selectively and dose-dependently activates NMUR2, exhibiting an EC50 value of 2.2 nM [1].